TTS typically manifests within a window of 4 to 28 days post-exposure to the AstraZeneca vaccine. Its hallmark features include a platelet count below 150 x 10^9/L and the emergence of thrombosis, notably in atypical sites such as cerebral venous sinuses and abdominal veins.

Former ICMR scientist Raman Gangakhedkar said the risk is highest after the initial dose, eventually decreasing with subsequent doses

Former ICMR scientist Dr Raman Gangakhedkar stated that a very small number of people may face the risk of rare side effects from the Covishield vaccine, including Thrombosis with Thrombocytopenia Syndrome (TTS).

In India, almost 90 per cent of people who received Covid-19 vaccine, received the AstraZeneca vaccine which in India is called Covishield

Only seven to eight individuals out of 10 lakh, who receive the coronavirus vaccine Covishield, face the risk of experiencing a rare side effect known as thrombosis thrombocytopenia syndrome (TTS). India’s top epidemiologist,